{"id":"NCT00366249","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.","officialTitle":"A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2006-08-21","resultsPosted":"2009-08-21","lastUpdate":"2010-04-28"},"enrollment":1061,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Infections","Diabetic Foot","Osteomyelitis"],"interventions":[{"type":"DRUG","name":"Tigecycline","otherNames":[]},{"type":"DRUG","name":"Ertapenem","otherNames":[]}],"arms":[{"label":"A","type":"ACTIVE_COMPARATOR"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.","primaryOutcome":{"measure":"Number of Patients With Clinical Response of Cure Vs. Failure.","timeFrame":"Test of cure visit (TOC): Assessed at least 12 days post last dose","effectByArm":[{"arm":"Tigecycline","deltaMin":316,"sd":null},{"arm":"Ertapenem","deltaMin":334,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":211,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Croatia","Denmark","Estonia","Finland","France","Germany","Greece","Hungary","India","Italy","Latvia","Lithuania","Mexico","Panama","Peru","Poland","Portugal","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["24439136"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":79},"commonTop":["Nausea","Vomiting","Diarrhea","Hypertension","Hypoglycemia"]}}